Narrow search
Showing 1 - 10 of 15
Cover Image
Specialty drug prices and utilization after loss of U.S. patent exclusivity, 2001-2007
Conti, Rena M.; Berndt, Ernst R. - National Bureau of Economic Research (NBER) - 2014
estimated prices of these drug undergoing LOE fall with generic entry. Second, we estimate reduced form random effects models of … utilization subsequent to LOE. We observe substantial price erosion after generic entry; average monthly price declines appear to … entry, but this result appears to be largely driven by oral drugs. We discuss second-best welfare consequences of these …
Persistent link: https://www.econbiz.de/10010950850
Cover Image
The Effect of FDA Advisories on Branded Pharmaceutical Firms' Valuations and Promotion Efforts
Conti, Rena M.; Huskamp, Haiden A.; Berndt, Ernst R. - National Bureau of Economic Research (NBER) - 2011
The US Food and Drug Administration (FDA) expends considerable efforts in regulating medications approved for use. Yet the impact of medication labeling changes on brand pharmaceutical products, and whether and what firms do to respond to increased information regarding the safety and efficacy...
Persistent link: https://www.econbiz.de/10009325511
Cover Image
Pricing and Reimbursement in U.S. Pharmaceutical Markets
Berndt, Ernst R.; Newhouse, Joseph P. - National Bureau of Economic Research (NBER) - 2010
comment on very recent developments concerning the entry of large retailers such as Wal-Mart into domains traditionally …
Persistent link: https://www.econbiz.de/10008531891
Cover Image
Vaccine Supply: Effects Of Regulation And Competition
Danzon, Patricia M.; Pereira, Nuno S. - National Bureau of Economic Research (NBER) - 2011
In US vaccine markets, competing producers with high fixed, sunk costs face relatively concentrated demand. The resulting price and quality competition leads to the exit of all but one or very few producers per vaccine. Our empirical analysis of exits from US vaccine markets supports the...
Persistent link: https://www.econbiz.de/10009151266
Cover Image
Brand Loyalty, Generic Entry and Price Competition in Pharmaceuticals in the Quarter Century After the 1984 Waxman-Hatch Legislation
Berndt, Ernst R.; Aitken, Murray L. - National Bureau of Economic Research (NBER) - 2010
following initial generic entry and by 24 months to 65, in 2009 the comparable generic price indexes are 68 and 27, respectively … patent has expired. Across all nine therapeutic areas, at 24 months post-generic entry, the weighted mean reduction in …
Persistent link: https://www.econbiz.de/10008682661
Cover Image
Costs, Institutional Mobility Barriers, and Market Structure: Advertising Agencies as Multiproduct Firms
Silk, Alvin J.; Berndt, Ernst R. - National Bureau of Economic Research (NBER) - 1994
low fixed costs and minimal entry barriers, both media-specific scale and scope economies are available and can be …
Persistent link: https://www.econbiz.de/10005248932
Cover Image
Pharmaceutical Pricing in Emerging Markets: Effects of Income, Competition and Procurement
Danzon, Patricia M.; Mulcahy, Andrew W.; Towse, Adrian K. - National Bureau of Economic Research (NBER) - 2011
This paper analyzes determinants of ex-manufacturer prices for originator and generic drugs across a large sample of countries. We focus on drugs to treat HIV/AIDS, TB and malaria in middle and low income countries (MLICs), with robustness checks to other therapeutic categories and other...
Persistent link: https://www.econbiz.de/10009147967
Cover Image
Value-Based Differential Pricing: Efficient Prices for Drugs in a Global Context
Danzon, Patricia M.; Towse, Adrian K.; … - National Bureau of Economic Research (NBER) - 2012
This paper analyzes pharmaceutical pricing between and within countries to achieve second best static and dynamic efficiency. We distinguish countries with and without universal insurance, because insurance undermines patients' price sensitivity, potentially leading to prices above second-best...
Persistent link: https://www.econbiz.de/10011272309
Cover Image
The Impact of Price Regulation on the Launch Delay of New Drugs - Evidence from Twenty-Five Major Markets in the 1990s
Danzon, Patricia M.; Wang, Liang; Wang, Y. Richard - National Bureau of Economic Research (NBER) - 2003
This study analyzes the effect of pharmaceutical price regulation on delays in new drug launches. Because low price in one market may 'spill-over' to others, though parallel trade and external referencing, manufacturers may rationally prefer longer delay or non-launch to accepting a low price....
Persistent link: https://www.econbiz.de/10005084850
Cover Image
Assessing the Impacts of the Prescription Drug User Fee Acts (PDUFA) on the FDA Approval Process
Philipson, Tomas; Berndt, Ernst R.; Gottschalk, Adrian H. B. - National Bureau of Economic Research (NBER) - 2004
Congress enacted and renewed the Prescription Drug User Fee Acts (PDUFA) in 1992, and renewed it in 1997 and 2002, mandating FDA performance goals in reviewing and acting on drug applications within specified time periods. In turn, the FDA was permitted to levy user fees on drug sponsors...
Persistent link: https://www.econbiz.de/10005084928